Go to the Globe and Mail homepage

Jump to main navigationJump to main content

(Getty Images)
(Getty Images)

NUMBER CRUNCHER

The biggest R&D spenders: Where innovation pays off Add to ...

Mr. Bowman is a portfolio manager at Wickham Investment Counsel Inc. michael@wickhaminvestments.com

What are we looking for?

Companies spending heavily on research and development. Even during times when the economy is struggling, businesses understand that a good R&D strategy is vital to their success. My colleague Allan Meyer put together this screen showing international companies that spend considerable portions of their revenue on R&D to see whether their stock prices have performed better than the market.

More Related to this Story

The screen

We searched for international companies that spend more than $100-million (U.S.) a year on R&D, and whose expenditures in this area were greater than their sales.

What did we find?

Our full list included 380 companies. Many companies you may not have heard of clustered around the top. Tesla Motors, for instance, spent more than $258.5-million on R&D, which was 102.3 per cent of its sales.

On the other hand, Apple, which you might have expected to be high in the ranking, finished way down at No. 348, spending only 2.2 per cent of net sales on R&D. The top Canadian company was Research In Motion, at No. 205. It spent 8.5 per cent of sales on R&D.

If there’s a lesson here, it’s that research does appear to pay off, although it’s no guarantee of success. The top 20 companies on the screen (shown) have averaged over 44.5 per cent return year to date. (Merrimack has only been around since April.)

Next time you are screening for stocks, consider looking at each company’s R&D costs as a percentage of net sales. Those companies that are able to keep customers happy with innovations and new ideas often find they have a leg up on the competition.

 

Companies spending heavily on R&D

Company Symbol R&D exp. 1 yr. ($ mil.) R&D/net sales %
Theravance THRX-Q 123.1 422.5
Ariad Pharma. ARIA-Q 112.6 307.3
Merrimack Pharma. MACK-Q 111.9 294.1
Incyte Corp. INCY-Q 197.0 189.2
Nektar Therapeut NKTR-Q 132.6 177.3
Seattle Genetics SGEN-Q 162.6 172.4
Isis Pharma. ISIS-Q 166.3 158.8
Ironwood Pharma. IRWD-Q 108.9 130.7
Regeneron Pharma. REGN-Q 543.2 118.8
Infinity Pharma. INFI-Q 116.4 117.0

Source: Wickham Investment Counsel, Bloomberg

Print

Download table as a CSV file

View full table

More Related to this Story

In the know

Most popular video »

Highlights

More from The Globe and Mail

Most Popular Stories